To better understand how peptides are classified, studied, and regulated, visit our Research Library.
For years, GLP-1 therapy meant injections. That just changed.
On December 22, 2025, the FDA approved oral Wegovy 25 mg, a once-daily pill version of semaglutide from Novo Nordisk, making it the first oral GLP-1 receptor agonist approved specifically for weight management. It’s also approved to reduce cardiovascular risk in adults with obesity and established heart disease.
The approval was supported by the OASIS-4 trial, which demonstrated meaningful weight loss as an adjunct to lifestyle changes.
And that’s just the start of the oral GLP-1 race. Eli Lilly’s orforglipron, a once-daily small molecule GLP-1 pill, is currently awaiting an FDA decision expected by Q2 2026, with Phase 3 data showing approximately 11% body weight reduction at the highest dose vs. 2% with placebo over 72 weeks.
For researchers studying GLP-1 receptor agonist mechanisms, the shift toward oral delivery opens entirely new questions around bioavailability, dosing kinetics, and patient adherence that injectable studies couldn’t address. For a broader context on how peptides are classified and regulated in the United States, see Are Peptides Legal in the United States.
Ongoing FDA enforcement is reshaping how peptides are marketed, sold, and studied across the industry. For deeper context on how the regulatory landscape is evolving, see the FDA peptide reclassification: what actually changed in 2026. For compound-specific research profiles, see the semaglutide research overview, the tirzepatide research overview, and the retatrutide research overview. For a full breakdown of the bioavailability challenges that make oral peptide delivery so difficult and what the research shows on solving them, see oral peptides research: the bioavailability challenge.
Prime Therapeutics — GLP-1 Pipeline Update, 2026
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment